Your browser doesn't support javascript.
loading
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study.
Kho, Pik Fang; Fawcett, Jonathan; Fritschi, Lin; Risch, Harvey; Webb, Penelope M; Whiteman, David C; Neale, Rachel E.
Affiliation
  • Kho PF; Population Health Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia.
  • Fawcett J; School of Medicine, University of Queensland, Brisbane, Australia.
  • Fritschi L; School of Medicine, University of Queensland, Brisbane, Australia.
  • Risch H; School of Public Health, Curtin University, Perth, Australia.
  • Webb PM; School of Public Health, Yale University, New Haven, CT, USA.
  • Whiteman DC; Population Health Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia.
  • Neale RE; School of Public Health, University of Queensland, Brisbane, Australia.
Cancer Causes Control ; 27(12): 1457-1464, 2016 Dec.
Article in En | MEDLINE | ID: mdl-27817122
ABSTRACT

PURPOSE:

Studies suggest that aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and statins may reduce risk of some cancers. However, findings have been conflicting as to whether these agents reduce the risk of pancreatic cancer.

METHODS:

We used data from the Queensland Pancreatic Cancer Study, a population-based case-control study. In total, 704 cases and 711 age- and sex-matched controls were recruited. Participants completed an interview in which they were asked about history of NSAID and statin use. We included 522 cases and 653 controls who had completed the medication section of the interview in this analysis. Unconditional multivariable logistic regression was used to estimate associations between medication use and pancreatic cancer.

RESULTS:

We found no consistent evidence of an association between use of NSAIDs or statins and risk of pancreatic cancer. There was some suggestion of a protective effect in infrequent users of selective COX-2 inhibitors, but no association in more frequent users. We did not find evidence of protective effects in analyses stratified by sex, smoking status, time between diagnosis and interview, or presence/absence of metastases.

CONCLUSIONS:

Overall, our results do support the hypothesis that use of NSAIDs or statins may reduce the odds of developing pancreatic cancer.
Subject(s)
Key words
Search on Google
Database: MEDLINE Main subject: Pancreatic Neoplasms / Anti-Inflammatory Agents, Non-Steroidal / Hydroxymethylglutaryl-CoA Reductase Inhibitors Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Cancer Causes Control Journal subject: EPIDEMIOLOGIA / NEOPLASIAS Year: 2016 Type: Article Affiliation country: Australia
Search on Google
Database: MEDLINE Main subject: Pancreatic Neoplasms / Anti-Inflammatory Agents, Non-Steroidal / Hydroxymethylglutaryl-CoA Reductase Inhibitors Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Oceania Language: En Journal: Cancer Causes Control Journal subject: EPIDEMIOLOGIA / NEOPLASIAS Year: 2016 Type: Article Affiliation country: Australia